AXSM
Axsome Therapeutics, Inc. NASDAQ Listed Nov 19, 2015$220.21
After hrs
$219.57
+1.01%
Mkt Cap $11.3B
52w Low $96.09
89.8% of range
52w High $234.29
50d MA $174.53
200d MA $149.24
P/E (TTM)
-56.1x
EV/EBITDA
-53.6x
P/B
116.4x
Debt/Equity
2.7x
ROE
-207.5%
P/FCF
-96.8x
RSI (14)
—
ATR (14)
—
Beta
0.47
50d MA
$174.53
200d MA
$149.24
Avg Volume
592.4K
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
22 Cortlandt Street · New York City, NY 10007 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | TNS | -0.85 | -1.26 | -48.2% | 223.70 | +1.1% | -0.3% | -0.5% | -1.6% | — | — | — |
| Feb 23, 2026 | TNS | -0.70 | -0.71 | -1.4% | 174.76 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% | — |
| Nov 3, 2025 | TNS | -0.82 | -0.94 | -14.6% | 135.75 | -1.3% | -0.6% | -0.0% | +2.7% | +1.8% | +1.5% | — |
| Aug 4, 2025 | TNS | -1.00 | -0.92 | +8.0% | 106.54 | -0.4% | -2.8% | -3.1% | -2.1% | -1.6% | -2.4% | — |
| May 5, 2025 | TNS | -1.26 | -0.80 | +36.5% | 116.49 | -0.6% | -3.7% | -4.8% | -6.5% | -7.5% | -5.4% | — |
| Feb 18, 2025 | TNS | -1.00 | -0.96 | +4.0% | 128.09 | +0.6% | -0.9% | +0.8% | +7.5% | +2.1% | -0.8% | — |
| Nov 12, 2024 | TNS | -1.38 | -1.34 | +2.9% | 99.49 | -0.5% | -1.7% | -2.1% | -6.4% | -7.1% | -4.1% | — |
| Aug 5, 2024 | TNS | -1.30 | -1.24 | +4.6% | 83.21 | +1.8% | +2.8% | +0.8% | +2.2% | -0.1% | +2.1% | — |
| May 6, 2024 | TNS | -1.20 | -1.09 | +9.2% | 75.94 | -0.5% | +1.3% | -0.3% | -3.0% | -4.5% | -0.4% | — |
| Feb 20, 2024 | TNS | -1.21 | -0.73 | +39.7% | 81.14 | -0.1% | +1.2% | -0.8% | -2.7% | +1.4% | +3.5% | — |
| Nov 6, 2023 | TNS | -1.24 | -1.32 | -6.5% | 62.42 | -1.1% | +1.1% | -1.4% | -3.8% | -8.0% | -5.0% | — |
| Aug 7, 2023 | TNS | -1.24 | -1.00 | +19.4% | 71.09 | +2.1% | +2.0% | -1.4% | -0.8% | -2.1% | +0.8% | — |
| May 8, 2023 | AMC | -1.13 | -0.22 | +80.5% | 77.73 | +0.0% | -1.3% | +3.2% | +0.3% | +1.6% | +0.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Needham | Maintains | Buy → Buy | — | $207.75 | $207.23 | -0.3% | -0.6% | +7.7% | +7.4% | +7.2% | +6.0% |
| Apr 10 | UBS | Maintains | Buy → Buy | — | $178.90 | $181.00 | +1.2% | -0.4% | -0.3% | +3.0% | +3.0% | +3.0% |
| Mar 25 | Guggenheim | Maintains | Buy → Buy | — | $158.75 | $160.74 | +1.3% | +1.9% | +3.5% | -1.5% | +1.1% | +6.5% |
| Feb 24 | Guggenheim | Maintains | Buy → Buy | — | $174.76 | $175.01 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% |
| Feb 24 | Wells Fargo | Maintains | Overweight → Overweight | — | $174.76 | $175.01 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% |
| Feb 24 | RBC Capital | Maintains | Outperform → Outperform | — | $174.76 | $175.01 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% |
| Feb 24 | UBS | Maintains | Buy → Buy | — | $174.76 | $175.01 | +0.1% | -2.8% | -6.0% | -6.6% | -6.2% | -4.8% |
| Feb 23 | Needham | Maintains | Buy → Buy | — | $183.72 | $176.42 | -4.0% | -4.9% | -7.5% | -10.6% | -11.2% | -10.8% |
| Feb 3 | Jefferies | Maintains | Buy → Buy | — | $185.88 | $188.25 | +1.3% | +0.8% | -0.2% | -2.7% | -1.8% | -1.4% |
| Jan 28 | Leerink Partners | Maintains | Outperform → Outperform | — | $188.02 | $187.69 | -0.2% | -1.5% | -1.5% | -2.0% | -1.1% | -0.4% |
| Jan 21 | RBC Capital | Maintains | Outperform → Outperform | — | $184.50 | $183.98 | -0.3% | +2.5% | +1.3% | +0.8% | +0.0% | +1.9% |
| Jan 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $177.27 | $178.00 | +0.4% | +4.1% | +6.7% | +5.5% | +4.9% | +4.1% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $174.14 | $175.71 | +0.9% | +1.8% | +5.9% | +8.6% | +7.4% | +6.8% |
| Jan 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $176.82 | $177.91 | +0.6% | -1.4% | +0.1% | -1.5% | +0.3% | +4.3% |
| Jan 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $170.69 | $168.97 | -1.0% | -1.8% | -0.8% | +3.6% | +2.1% | +3.7% |
| Jan 6 | UBS | Maintains | Buy → Buy | — | $171.49 | $173.00 | +0.9% | +0.2% | -0.5% | -2.3% | -1.2% | +3.1% |
| Jan 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $178.69 | $178.88 | +0.1% | -4.0% | -3.8% | -4.5% | -6.2% | -5.2% |
| Dec 31 | Needham | Maintains | Buy → Buy | — | $148.79 | $158.49 | +6.5% | +22.8% | +20.1% | +15.3% | +15.5% | +14.7% |
| Nov 6 | Mizuho | Maintains | Outperform → Outperform | — | $135.69 | $135.66 | -0.0% | +2.7% | +1.8% | +1.6% | +2.9% | +3.8% |
| Nov 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $135.75 | $134.01 | -1.3% | -0.6% | -0.0% | +2.7% | +1.8% | +1.5% |
| Nov 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $135.75 | $134.01 | -1.3% | -0.6% | -0.0% | +2.7% | +1.8% | +1.5% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $135.75 | $134.01 | -1.3% | -0.6% | -0.0% | +2.7% | +1.8% | +1.5% |
| Nov 4 | RBC Capital | Maintains | Outperform → Outperform | — | $135.75 | $134.01 | -1.3% | -0.6% | -0.0% | +2.7% | +1.8% | +1.5% |
| Nov 4 | Guggenheim | Maintains | Buy → Buy | — | $135.75 | $134.01 | -1.3% | -0.6% | -0.0% | +2.7% | +1.8% | +1.5% |
| Nov 4 | Needham | Maintains | Buy → Buy | — | $135.75 | $134.01 | -1.3% | -0.6% | -0.0% | +2.7% | +1.8% | +1.5% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $127.94 | $129.71 | +1.4% | +2.9% | +2.7% | +1.4% | -0.7% | +1.3% |
| Aug 6 | UBS | Maintains | Buy → Buy | — | $103.59 | $102.37 | -1.2% | -0.3% | +0.7% | +1.2% | +0.4% | +1.6% |
| Aug 5 | RBC Capital | Maintains | Outperform → Outperform | — | $106.54 | $106.12 | -0.4% | -2.8% | -3.1% | -2.1% | -1.6% | -2.4% |
| Aug 5 | BofA Securities | Maintains | Buy → Buy | — | $106.54 | $106.12 | -0.4% | -2.8% | -3.1% | -2.1% | -1.6% | -2.4% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $103.02 | $108.00 | +4.8% | +3.4% | +0.6% | +0.2% | +1.3% | +1.7% |
| Jun 12 | RBC Capital | Maintains | Outperform → Outperform | — | $108.08 | $107.32 | -0.7% | -1.7% | -3.7% | -5.9% | -6.0% | -4.8% |
| Jun 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $109.87 | $110.12 | +0.2% | +0.0% | -1.6% | -3.3% | -5.3% | -7.4% |
| Jun 9 | Needham | Maintains | Buy → Buy | — | $111.91 | $110.50 | -1.3% | -1.8% | -1.8% | -3.4% | -5.1% | -7.0% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $105.76 | $105.16 | -0.6% | -1.3% | -0.7% | -1.7% | -2.6% | -1.1% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $112.16 | $111.15 | -0.9% | -1.2% | -2.9% | -3.9% | -1.8% | -5.8% |
| May 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $116.49 | $115.76 | -0.6% | -3.7% | -4.8% | -6.5% | -7.5% | -5.4% |
| May 6 | Baird | Maintains | Outperform → Outperform | — | $116.49 | $115.76 | -0.6% | -3.7% | -4.8% | -6.5% | -7.5% | -5.4% |
| Apr 29 | RBC Capital | Maintains | Outperform → Outperform | — | $107.24 | $107.62 | +0.4% | +2.5% | +4.7% | +4.7% | +4.6% | +8.6% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $109.75 | $107.46 | -2.1% | -1.7% | -9.9% | -10.3% | -11.1% | -7.4% |
| Apr 1 | Needham | Maintains | Buy → Buy | — | $116.63 | $112.43 | -3.6% | -4.3% | -5.9% | -7.5% | -15.2% | -15.5% |
| Mar 27 | Mizuho | Maintains | Outperform → Outperform | — | $119.16 | $120.19 | +0.9% | +2.2% | -0.5% | -2.1% | -6.3% | -7.9% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $125.10 | $123.51 | -1.3% | -0.6% | -2.3% | -5.1% | -4.5% | -4.5% |
| Mar 4 | RBC Capital | Maintains | Outperform → Outperform | — | $127.15 | $125.84 | -1.0% | -1.2% | -1.6% | -2.2% | -3.9% | -6.6% |
| Mar 3 | Baird | Maintains | Outperform → Outperform | — | $127.54 | $130.00 | +1.9% | -0.3% | -1.5% | -1.9% | -2.5% | -4.2% |
| Mar 3 | Needham | Maintains | Buy → Buy | — | $127.54 | $130.00 | +1.9% | -0.3% | -1.5% | -1.9% | -2.5% | -4.2% |
| Feb 27 | Morgan Stanley | Maintains | Overweight → Overweight | — | $128.33 | $129.53 | +0.9% | -1.5% | -0.6% | -0.9% | -2.2% | -2.5% |
| Feb 26 | Mizuho | Maintains | Outperform → Outperform | — | $127.09 | $128.09 | +0.8% | +1.0% | -0.5% | +0.4% | +0.0% | -1.2% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $130.72 | $130.88 | +0.1% | -2.8% | -1.8% | -3.3% | -2.4% | -2.7% |
| Feb 24 | Needham | Maintains | Buy → Buy | — | $137.75 | $137.76 | +0.0% | -5.1% | -7.7% | -6.8% | -8.2% | -7.4% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $126.96 | $128.13 | +0.9% | +1.7% | +8.5% | +3.0% | +0.1% | +1.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | Sell | 233 | $228.18 | $53K | — | -0.19% | — |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | Sell | 4,517 | $227.94 | $1.0M | — | -0.19% | — |
8-K · 2.02
!! High
Axsome Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Axsome Therapeutics reported quarterly earnings results, with financial details available in the attached press release for investor review of operational performance.
May 4
8-K · 8.01
!! High
Axsome Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
FDA approval of Axsome's AUVELITY for Alzheimer's dementia-related agitation expands the company's commercial opportunity in neurology and validates its therapeutic approach for this patient population.
Apr 30
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Axsome is acquiring TAK-063, an oral PDE10A inhibitor with potential in neuropsychiatric disorders, expanding its CNS pipeline and diversifying its portfolio beyond current offerings.
Apr 1
8-K
Axsome Therapeutics, Inc -- 8-K Filing
Axsome Therapeutics reported 2025 financial results and provided a business update, with the filing signed by CEO Herriot Tabuteau on February 23, 2026.
Feb 23
8-K · 8.01
!! High
Axsome Therapeutics, Inc -- 8-K 8.01: Material Event / Announcement
Axsome Therapeutics resolved patent litigation with Alkem regarding SUNOSI, eliminating a legal threat to the drug's market exclusivity in the United States.
Feb 17
Data updated apr 24, 2026 8:15pm
· Source: massive.com